SUPN on Nasdaq

SUPERNUS PHARMACEUTICALS, INC.

American pharmaceutical preparations company based in Rockville. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Amphastar Pharmaceuticals, Inc., Pacira BioSciences, Inc. or Emergent BioSolutions, or pick any stock.

  • TickerSUPN on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersRockville, United States2
  • Incorporated inDE3
  • Business address9715 Key West Avenue, Rockville, Md 208503
  • Filer categoryLarge accelerated filer3
  • Legal formCorporation2
  • LEI549300GRM36VBKISYJ582
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 39475842

See how the biggest companies compare on our leaderboards

Supernus Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a broad range of novel product candidates for CNS disorders.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-8.7%Operating margin5
-5.4%Net margin5
8.6%Revenue growth, 20255
-3.6%Return on equity5
$46.0MFree cash flow5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Qelbree brought in 42% of the revenue SUPERNUS PHARMACEUTICALS, INC. broke down this way in fiscal 2025.

  1. Qelbree$304.7M542%up 26% from 2024
  2. Gocovri$146.8M520%up 12% from 2024
  3. Collaboration Revenue$53.0M57%
  4. Apokyn$47.8M57%down 35% from 2024
  5. Trokendi Xr$42.4M56%down 33% from 2024
  6. Oxtellar X R$40.7M56%down 59% from 2024
  7. Royalty, License And Other Revenue$39.4M55%up 63% from 2024
  8. Manufactured Product, Other$26.9M54%down 7% from 2024
  9. Onapgo$17.3M52%
Products and services by year
Products and services202320242025
Qelbree$140.2M$241.3M$304.7M
Gocovri$119.6M$130.8M$146.8M
Collaboration Revenue$0$0$53.0M
Apokyn$75.1M$73.9M$47.8M
Trokendi Xr$94.3M$63.2M$42.4M
Oxtellar X R$113.4M$99.5M$40.7M
Royalty, License And Other Revenue$33.6M$24.1M$39.4M
Manufactured Product, Other$31.3M$29.0M$26.9M
Onapgo$0$0$17.3M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue10¢$74.6M
  • Research and development15¢$106.2M
  • Selling, general and admin68¢$485.6M
  • Other costs6¢$42.1M
  • Income tax1¢$10.5M

Out of $719.0M in revenue.5 The company lost money this year.

Where each dollar of operating cash went, fiscal 2025

  • Capital spending3¢$1.3M
  • Kept or used elsewhere97¢$46.0M

Out of $47.3M of cash from operations.5

Financial statements

Revenue6785$719.0M in 2025+83% since 2019
0$200.0M$400.0M$600.0M$800.0M2019: $392.8M$392.8M20192020: $520.4M$520.4M2020+32%2021: $579.8M$579.8M2021+11%2022: $667.2M$667.2M2022+15%2023: $607.5M$607.5M2023−9%2024: $661.8M$661.8M2024+9%2025: $719.0M$719.0M2025+9%
Operating income6785-$62.3M in 2025
-$100.0M0$100.0M$200.0M2019: $148.6M$148.6M20192020: $173.7M$173.7M2020+17%2021: $86.0M$86.0M2021−50%2022: $46.1M$46.1M2022−46%2023: -$5.3M-$5.3M20232024: $81.7M$81.7M20242025: -$62.3M-$62.3M2025
Net income6785-$38.5M in 2025
-$50.0M0$50.0M$100.0M$150.0M2019: $113.1M$113.1M20192020: $127.0M$127.0M2020+12%2021: $53.4M$53.4M2021−58%2022: $60.7M$60.7M2022+14%2023: $1.3M$1.3M2023−98%2024: $73.9M$73.9M2024+5513%2025: -$38.5M-$38.5M2025

Every line of the income statement as filed: the last 3 fiscal years, latest first.5

Period ending2025-12-312024-12-312023-12-31
Total revenues$719.0M$661.8M$607.5M
Cost of revenues$74.6M$77.9M$83.8M
Research and development$106.2M$108.8M$91.6M
Selling, general and administrative$485.6M$321.6M$336.4M
Amortization of intangible assets$89.5M$78.0M$82.4M
Intangible asset impairment charges$0$0$20.2M
Contingent consideration loss (gain)$25.4M-$6.1M-$1.5M
Total costs and expenses$781.2M$580.2M$612.8M
Operating earnings (loss)-$62.3M$81.7M-$5.3M
Interest and other income, net$13.3M$16.2M$10.5M
Interest expense$0$0-$2.4M
Total other income (expense), net$13.3M$16.2M$8.0M
Earnings (loss) before income taxes-$49.0M$97.9M$2.8M
Income tax expense (benefit)-$10.5M$24.0M$1.5M
Net earnings (loss)-$38.5M$73.9M$1.3M
Basic (in dollars per share)-$0.68$1.34$0.02
Diluted (in dollars per share)-$0.68$1.32$0.02
Basic (in shares)56.5M shares55.1M shares54.5M shares
Diluted (in shares)56.5M shares56.0M shares55.5M shares

Compare SUPERNUS PHARMACEUTICALS, INC. with another company

Leadership

Who has led SUPERNUS PHARMACEUTICALS, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jack A. Khattar2012–now

President

  1. Jack A. Khattar2012–2021
  2. Timothy C. Dec2021–now

Chief financial officer

  1. Gregory S. Patrick2012–2020
  2. Timothy C. Dec2021–now
201520202025
Board members and other officers (19)

Former names

  • SUPERNUS PHARMACEUTICALS INCMar 6, 2006 to Jun 12, 20193

Timeline

  1. Apr 30, 2012New chief executive Jack A. Khattar becomes CEO12
  2. Mar 30, 2005Founded SUPERNUS PHARMACEUTICALS, INC. is founded2

Filings

527 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 95 major events, 279 insider forms, 26 large holders, 107 other. The latest 20:

  1. Oct 15, 20268-K EDGAR
  2. Oct 6, 2026425 EDGAR
  3. Oct 6, 2026DEFA14A EDGAR
  4. Sep 11, 2026DEFM14A EDGAR
  5. Aug 14, 20264 EDGAR
  6. Aug 14, 20264 EDGAR
  7. Aug 14, 20264 EDGAR
  8. Aug 14, 20264 EDGAR
  9. Aug 14, 20264 EDGAR
  10. Aug 6, 2026SCHEDULE 13G/A EDGAR
  11. Aug 4, 2026425 EDGAR
  12. Aug 3, 202610-Q EDGAR
  13. Aug 3, 20268-K EDGAR
  14. Aug 3, 2026425 EDGAR
  15. Aug 3, 2026DEFA14A EDGAR
  16. Aug 3, 2026425 EDGAR
  17. Aug 3, 20268-K EDGAR
  18. Aug 3, 2026DEFA14A EDGAR
  19. Aug 3, 2026425 EDGAR
  20. Aug 3, 20268-K EDGAR

The 527 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

87 open-market trades by officers, directors and large owners since October 2021: 0 buys and 87 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 18, 2026Bhatt Padmanabh P.Sr. VP of IP, CSOSale7,250$49.60$359.6KForm 4
Mar 17, 2026Bhatt Padmanabh P.Sr. VP of IP, CSOSale50,000$50.30$2.5MForm 4
Mar 16, 2026Bhatt Padmanabh P.Sr. VP of IP, CSOSale50,000$50.28$2.5MForm 4
Mar 13, 2026Khattar Jack A.President, CEOSale35,000$50.38$1.8MForm 4
Mar 12, 2026Hudson Frederick M.DirectorSale5,369$50.61$271.7KForm 4
Mar 10, 2026Horich William ToddSVP, Commercial OperationsSale4,439$55.00$244.1KForm 4
Mar 9, 2026Horich William ToddSVP, Commercial OperationsSale4,438$54.00$239.7KForm 4
Mar 9, 2026Mottola FrankSVP, Chief Tech. Ops. OfficerSale1,623$53.65$87.1KForm 4
Mar 6, 2026GEMAYEL GEORGESDirectorSale8,787$53.00$465.7KForm 4
Mar 5, 2026GEMAYEL GEORGESDirectorSale10,000$53.71$537.1KForm 4
Feb 19, 2026Sensenig BethanyDirectorSale4,475$51.01$228.3KForm 4
Dec 19, 2025Mottola FrankSVP, Chief Tech. Ops. OfficerSale20,000$50.41$1.0MForm 4
Dec 18, 2025Bhatt Padmanabh P.Sr. VP of IP, CSOSale710$44.44$31.6KForm 4
Oct 9, 2025Khattar Jack A.President, CEOSale59,900$50.57$3.0MForm 4
Oct 9, 2025NEWHALL CHARLES W IIIDirectorSale25,000$50.77$1.3MForm 4
Oct 2, 2025Khattar Jack A.President, CEOSale1,904$48.06$91.5KForm 4
Oct 1, 2025Khattar Jack A.President, CEOSale40,173$48.07$1.9MForm 4
Sep 30, 2025Khattar Jack A.President, CEOSale8,588$48.25$414.4KForm 4
Sep 29, 2025Khattar Jack A.President, CEOSale10,235$48.02$491.5KForm 4
Sep 23, 2025Khattar Jack A.President, CEOSale29,513$47.23$1.4MForm 4

All 87 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.9,350,046$434.9M0.0%+552,792
Millennium Management LLC3,853,212$179.2M0.1%+537,239
Vanguard Portfolio Management LLC3,305,429$153.7M0.0%+66,736
Armistice Capital, LLC2,646,201$123.1M3.4%+750,854
Vanguard Capital Management LLC2,516,721$117.1M0.0%+49,506
State Street Corp2,459,828$114.4M0.0%+171,701
Nomura Asset Management International Inc.2,378,329$110.6M0.2%+341,127
Dimensional Fund Advisors LP2,078,090$96.7M0.0%−228,940
Geode Capital Management, LLC1,570,088$73.0M0.0%−53,426
Stephens Investment Management Group LLC1,485,821$69.1M0.7%+134,490
Renaissance Technologies LLC1,478,180$68.8M0.1%−227,042
Loomis Sayles & Co L P1,475,192$68.6M0.1%+49,413
Citadel Advisors LLC1,373,982$63.9M0.0%−119,464
Two Sigma Investments, LP1,184,378$55.1M0.0%+913,150
Sofinnova Investments, Inc.1,036,328$48.2M2.6%+82,019
Qube Research & Technologies Ltd922,166$42.9M0.0%+423,968
Morgan Stanley876,841$40.8M0.0%−37,052
Goldman Sachs Group Inc819,432$38.1M0.0%−37,055
D. E. Shaw & Co., Inc.767,668$35.7M0.0%+145,218
Northern Trust Corp733,374$34.1M0.0%+33,918
Woodline Partners LP708,276$32.9M0.1%+259,280
Charles Schwab Investment Management Inc703,552$32.7M0.0%−2,424
Bank Of America Corp /de/621,102$28.9M0.0%−93,124
Ashford Capital Management Inc613,783$28.5M3.1%−31,598
Soleus Capital Management, L.P.520,000$24.2M0.8%New

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

9 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Mar 3, 2026Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−40.3%Report
Dec 11, 2025Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−26.2%Report
Oct 9, 2025Gilbert Ray Cisneros, Jr.Democratic, HousePartial sale$1,001 - $15,000+34.4%Report
Mar 24, 2025Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−12.4%Report
Dec 23, 2022Josh GottheimerDemocratic, HousePartial sale$1,001 - $15,000+95.0%Report
Nov 13, 2020Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−42.1%Report
Jul 17, 2020Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−75.0%Report
Jun 1, 2020Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−85.3%Report
May 28, 2020Josh GottheimerDemocratic, HouseBuy$1,001 - $15,000−91.8%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39